Abstract: Interleukin (IL)-27 is a novel cytokine secreted by stimulation of antigen-presenting cells. No previous studies currently reported the role of IL-27 in the carcinogenesis of osteosarcoma. We aimed to investigate the association of IL-27 polymorphisms and serum IL-27p28 with osteosarcoma risk in a Chinese population.

One hundred and sixty osteosarcoma patients and 250 health controls were selected. IL-27 gene -964 A/G, 2905 T/G, and 4730 T/C polymorphisms were determined by using polymerase chain reaction-restriction fragment length polymorphism. Enzyme-linked immunosorbent assay were used to detect serum IL-27p28 levels.

The serum IL-27p28 levels were significantly lower in osteosarcoma patients compared with those in controls (P < 0.01). Serum IL-27p28 levels in stages III–IV were lower than those in stages I–II of osteosarcoma (P < 0.05); the similar results were also found in patients with metastasis, that is, patients with metastasis have higher IL-27p28 levels than those without metastasis (P < 0.05). There were no associations between genotype and allele frequencies of IL-27 -964 A/G, 2905 T/G, 4730 T/C, and the risk of osteosarcoma (P > 0.05). Stratification analysis also failed to show the associations between -964 A/G, 2905 T/G, and 4730 T/C polymorphisms and the clinical stage and metastasis of osteosarcoma (P > 0.05). Three possible haplotypes (A-964T2905T4730, G-964T2905C4730, and G-964G2905C4730) were identified, but no associations were found between them and the osteosarcoma risk (P > 0.05).

This study indicates that the lower serum IL-27p28 levels may be associated with development and progression of osteosarcoma, but IL-27 gene -964 A/G, 2905 T/G, and 4730 T/C polymorphisms and their haplotypes are not associated with osteosarcoma risk.

Abbreviations: CI = confidence interval, COPD = chronic obstructive pulmonary disease, IBD = inflammatory bowel disease, IL = interleukin, HWE = Hardy–Weinberg equilibrium, LD = linkage disequilibrium, OR = odds ratio.

INTRODUCTION

Osteosarcoma is an aggressive malignant neoplasm arising from primitive transformed cells of mesenchymal. It is the most common histological form of primary bone cancer and mostly occurs in adolescents and people over 50 years of age.1 Osteosarcoma is featured by the differentiation of osteoblastic and production of malignant osteoid.2 The exact etiology of osteosarcoma remains to be elucidated. For many years, accumulated evidences suggested that multiple genetic and environmental factors play pivotal roles in the pathogenesis of osteosarcoma.3 Currently, there are studies indicating that the main mechanism of immune defense system against cancer is dependent on T cell response.4 Therefore, the polymorphisms of genes encoding T cell response molecules may potentially affect the development of tumors.2

Interleukin (IL)-27 is a member of the same family as IL-12 and IL-23. IL-27 is involved in the process of the differentiation of Th1 lymphocytes, enhancement of the cellular type immune response, and the reciprocal inhibition of Th2 humoral immune reactions.5 Evidences have demonstrated that IL-27 can inhibit tumor progression through several mechanisms, regardless of tumor immunogenicity; these characters potentially make it a valuable agent in the treatment of tumors.7 Human IL-27 is located at chromosome 16p11 and secreted as a heterodimer that consists of the Epstein–Barr-induced gene 3 (EBI3) product and p28. EBI3 subunit has sequence homology with IL-12p40,8 and the heterodimeric IL-27p28 chain belongs to the family of long-chain 4-helix bundle cytokines and displays sequence homology to IL-12p35 and IL-23p19.9 Recently, the associations of IL-27 -964 A/G, 2905 T/G, and 4730 T/C polymorphisms with the risk for various diseases were investigated and the relationships between -964 A/G and the risk for several diseases such as asthma,10 chronic obstructive pulmonary disease (COPD),11 and inflammatory bowel disease (IBD12) have been identified.

Previously, studies have investigated the association between IL-27 gene polymorphisms and several tumors, such as esophageal cancer,13 nasopharyngeal carcinoma,14 glioma,15 and colorectal cancer.16 However, little is known about the role of IL-27 gene polymorphisms in the carcinogenesis of osteosarcoma. A better understanding of the association between IL-27 gene polymorphism and osteosarcoma risk may identify an important role of IL-27 in the carcinogenesis of osteosarcoma.
osteosarcoma, which provides clues that help to guide the treatment of this tumor. Therefore, to clarify this association, we analyzed the IL-27 gene -964 A/G (rs153109), 2905 T/G (rs17855750), and 4730 T/C (rs181206) and their haplotypes in osteosarcoma and normal controls in a Chinese population.

MATERIALS AND METHODS

Study Population
This case-control population study is hospital based and consists of 160 osteosarcoma patients and 250 healthy controls. The osteosarcoma patients were enrolled from the Affiliated Hospital of Youjiang Medical College for Nationalities and the First Affiliated Hospital of Jinan University between 2005 and 2013. The diagnosis of osteosarcoma was based on pathology test and none of the patients had familial cancer history. The healthy controls were those who visited the hospitals at the same period for general health checkup, and they have no evidences of personal or family history of cancer or other serious illness. Clinical stage of these osteosarcoma patients was classified according to the 6th edition of the tumor, node, metastasis classification of the International Union Against Cancer. All of the patients had no autoimmune diseases before their hospitalization. At the time of sample collection, none of the patients had received any anticancer therapy, corticosteroids, doxorubicin, or other nonsteroid anti-inflammatory drugs that may compromise the function of the immune system. The controls were matched with the patient population in terms of age, sex, and residence area. All participants were unrelated ethnic Han Chinese. Written informed consent was obtained from each participant. The study was approved by the Review Boards of the Affiliated Hospital of Youjiang Medical College for Nationalities.

Serum IL-27p28 and IL-12p40 Determination
Serum samples were collected from venous blood at room temperature and stored at −80°C until use. The quantitative determination of serum IL-27p28 was performed by enzyme-linked immunosorbent assay kits (Fermentas China Co, Ltd, Shenzhen, China) according to the manufacturer’s instruction. Developed color reaction was measured as OD450 units on an enzyme-linked immunosorbent assay reader (BIO-RAD 680, Tokyo, Japan). The concentration of cytokines was determined using standard curve constructed with the kit’s standards over the range of 0–10,000 pg/mL.

DNA Extraction
Genomic DNA was extracted from ethylene diamine tetraacetate acid anticoagulated peripheral blood leukocytes by the salting-out method. Briefly, 3 mL of blood was mixed with Triton lysis buffer (0.32 M sucrose, 1% Triton100, 5 mM MgCl2, H2O, 10 mM Tris–HCl, and pH 7.5). Leucocytes were spun down and washed with H2O. The pellet was incubated with proteinase K at 56°C and subsequently salted out at 4°C using a saturated NaCl solution. Precipitated proteins were removed by centrifugation. The DNA in the supernatant fluid was dissolved in 300 μL H2O.

Genotype of IL-27 Variants
The IL-27 gene -964 A/G, 2905 T/G, and 4730 T/C genotypes were determined using a polymerase chain reaction (PCR)-restriction fragment length polymorphism method. The PCR primers were designed based on the GenBank reference sequence (No. EF064720) as we previously described.14,16

Statistical Analysis
Comparisons were carried out using Student’s t-test or χ2 test for 2-group comparisons when appropriate. Correlations were determined by Pearson’s correlation test. Genotype and allele frequencies of IL-27 among groups were compared by using the χ2 test and Fisher’s exact test when appropriate, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relative risk conferred by a particular allele and genotype. The goodness of fit test for Hardy–Weinberg equilibrium (HWE), calculating the expected frequencies of each genotype and comparing them with the observed values for subjects, was performed using χ2 test. The linkage disequilibrium (LD) among the polymorphisms was quantified using the Shi’s standardized coefficient D′(D′). The haplotypes and their frequencies were estimated based on a Bayesian algorithm using the Phase program.2 Statistical significance was assumed at the P < 0.05 level. The SPSS statistical software package version 16.0 (SPSS, Chicago, IL) was used for all of the statistical analysis.

RESULTS

Clinical Characteristics of the Study Participants
The demographics and clinical characteristics of the osteosarcoma patients and controls in this study are shown in Table 1. There were no significant differences with respect to the age and gender distributions between osteosarcoma patients and controls (P > 0.05).

Serum Levels of IL-27p28 and IL-12p40
The serum IL-27p28 levels were significantly elevated in healthy controls (243.7 ± 108.5 pg/mL) compared with those in osteosarcoma patients (158.6 ± 97.3 pg/mL, P < 0.01). We also found that serum IL-12p40 levels were distinctly elevated in healthy controls (268.2 ± 107.4 pg/mL) compared with osteosarcoma patients (201.2 ± 90.3 pg/mL, P < 0.01). Correlation

Table S1 (http://links.lww.com/MD/A33) presented primer sequences and reaction conditions. The PCR was carried out as in our previous study.14 To confirm the genotyping results, PCR-amplified DNA samples were examined by DNA sequencing and the results were 100% concordant.

Table 1. Characteristics of the Study Population

| Variable          | Osteosarcoma (n = 160) | Controls (n = 250) | P   |
|-------------------|------------------------|-------------------|-----|
| Mean age, y       | 27.5 ± 8.5             | 27.9 ± 7.8        | 0.625|
| >20               | 51 (31.9)              | 75 (30.0)         | 0.688|
| ≤20               | 109 (68.1)             | 175 (70.0)        |      |
| Gender n (%)      |                        |                   |     |
| Male              | 105 (65.6)             | 155 (62.0)        | 0.457|
| Female            | 55 (34.4)              | 95 (38.0)         |      |
| Tumor location n (%) |                   |                   |     |
| Long tubular bones| 133 (83.1)             | 141 (56.4)        |      |
| Axial skeleton    | 27 (16.9)              | 149 (53.6)        |      |
| Metastasis        |                        |                   |     |
| Yes               | 56 (35.0)              |                   |      |
| No                | 104 (65.0)             |                   |      |
analysis revealed that IL-27p28 was correlated with IL-12p40 ($r = 0.567, P = 0.004$).

**Relationship of Serum IL-27p28 and Clinical Features of Osteosarcoma**

The results showed that serum IL-27p28 levels in stages III–IV were lower than those in stages I–II of osteosarcoma ($P < 0.05$); and patients with metastasis have higher IL-27p28 levels than those without metastasis ($P < 0.05$). However, no significant differences were found with respect to patients’ age, gender, tumor size, histological type, and tumor location ($P > 0.05$) (Table 2).

**IL-27 Polymorphisms With Respect to Serum IL-27p28 Levels in Osteosarcoma**

No significant differences of the IL-27 gene polymorphisms (-964 A/G, 2905 T/G, and 4730 T/C) were detected with respect to serum IL-27p28 levels in osteosarcoma (see Table 3).

**Genotype and Allele Frequencies of IL-27 Polymorphisms in Osteosarcoma**

The genotype and allele frequencies of IL-27 -964 A/G, 2905 T/G, and 4730 T/C polymorphisms between osteosarcoma patients and controls are shown in Table 4. The genotype distributions of the 3 polymorphisms between the osteosarcoma patients and the controls were all in agreement with HWE (data not shown). However, genotype and allele frequencies of IL-27 -964 A/G, 2905 T/G, and 4730 T/C polymorphisms of osteosarcoma were not associated with osteosarcoma risk ($P > 0.05$).

**Distribution of IL-27 Genotype With Clinical Parameters of Osteosarcoma**

No associations were found between IL-27 -964 A/G, 2905 T/G, and 4730 T/C polymorphisms and the location, metastasis, and clinical stage of osteosarcoma ($P > 0.05$). See Table S2, http://links.lww.com/MD/A34, which illustrates the distribution of IL-27 genotype with clinical parameters of osteosarcoma.

**Haplotype Analysis of the IL-27 Polymorphisms**

Three possible haplotypes were constructed and shown in Table 5 (haplotype frequency <5% was ignored in the table). LD was observed between locus -964 and locus 2905 ($D^0 = 0.998$), locus -964 and locus 4730 ($D^0 = 0.998$), and locus 2905 and locus 4730 ($D^0 = 0.985$). The majority of the

---

### Table 2. Serum IL-27p28 and Clinical Features of Osteosarcoma

| Age, y  | n | IL-27p28, pg/mL | $P$  |
|---------|---|-----------------|------|
| $\geq 20$ | 51 | 162.4 ± 94.8 | 0.534 |
| $<20$    | 109 | 153.6 ± 77.3 |  |
| Gender   |              |                |      |
| Male     | 105 | 160.2 ± 90.5 | 0.725 |
| Female   | 55  | 155.4 ± 61.7 |  |
| Tumor size, cm | | | |
| $\geq 7$ | 88  | 148.8 ± 71.2 | 0.186 |
| $<7$     | 72  | 166.5 ± 96.2 |  |
| Histological type | | | |
| Osteoblastic | 88  | 152.3 ± 72.1 |  |
| Teleangiectatic | 20  | 160.4 ± 90.2 |  |
| Chondroblastic | 17  | 157.9 ± 71.7 | 0.518 |
| Fibroblastic | 18  | 159.3 ± 78.5 |  |
| Undifferentiated | 17  | 157.8 ± 91.9 |  |
| Tumor location | | | |
| Long tubular bones | 133 | 158.4 ± 96.5 | 0.778 |
| Axial skeleton | 27  | 152.7 ± 92.1 |  |
| Clinical stage | | | |
| I–II | 76  | 137.2 ± 55.6 | 0.003 |
| III–IV | 84  | 169.2 ± 92.8 |  |
| Metastasis | | | |
| Yes | 56  | 130.4 ± 58.3 | 0.022 |
| No | 104 | 161.9 ± 92.4 |  |

IL = interleukin.

---

### Table 3. IL-27 Polymorphisms With Respect to Serum IL-27p28 Levels

| IL-27  | n | IL-27p28, pg/mL | $P$  |
|--------|---|-----------------|------|
| -964 A/G | AA | 56  | 152.8 ± 98.6 | 0.669 |
|         | AG + GG | 104 | 146.3 ± 87.5 |  |
| 2905 T/G | TT | 132 | 161.8 ± 103.7 | 0.745 |
|         | TG + GG | 28  | 154.8 ± 101.9 |  |
| 4730 T/C | TT | 131 | 147.2 ± 87.6 | 0.373 |
|         | TC + CC | 29  | 163.4 ± 92.1 |  |

IL = interleukin.

---

### Table 4. Genotype and Allele Frequencies of IL-27 Polymorphism in Osteosarcoma and Controls

| Poly-morphism | Osteosarcoma (n = 160) | Controls (n = 250) | OR (95% CI) | $P$  |
|---------------|-------------------------|-------------------|-------------|------|
| IL-27 -964 A/G | AA | 56 (35.0) | 100 (40.0) | 1.00 |
|               | AG | 85 (53.1) | 124 (49.6) | 1.22 (0.80–1.88) | 0.355 |
|               | GG | 19 (11.9) | 26 (10.4) | 1.31 (0.66–2.57) | 0.440 |
| IL-27 2905 T/G  | TT | 132 (82.5) | 205 (82.0) | 1.00 |
|               | TG | 28 (17.5) | 45 (18.0) | 0.97 (0.58–1.63) | 0.897 |
| IL-27 4730 T/C  | TT | 131 (81.9) | 207 (82.8) | 1.00 |
|               | TC | 29 (18.1) | 43 (17.2) | 1.07 (0.63–1.79) | 0.810 |
|               | CC | 0 (0) | 0 (0) | — | — |
|               | T  | 291 (92.1) | 457 (91.4) | 1.00 |
|               | G  | 28 (8.8) | 45 (9.0) | 1.03 (0.61–1.76) | 0.902 |

CI = confidence interval, IL = interleukin, OR = odds ratio.
lymphocytes and natural killer cells. IL-27 is also known to mediate a number of biological effects, including the induction of interferon-γ-inducing protein (interferon inducible protein-10/CXCL9). Both molecules were able to inhibit angiogenesis and tumor growth and metastasis through their antiangiogenic effects. Yoshimoto et al. discovered that IL-27 was able to perform direct antiproliferative effects on several WSX-1-positive human melanoma lines. Shimizu et al. indicated that IL-27-transduced tumors have lower microvessel density and grow more slowly than parental tumors. Taken together, the current evidences suggested that IL-27 can inhibit both primary and metastatic tumor, which potentially makes it a valuable therapeutic agent in the treatment of cancer.

It is important to note that, besides IL-27, there are other heterodimeric ILs, such as IL-23, IL-12, and IL-35 and both IL-27 and IL-12 are secreted by dendritic cells. Therefore, by determining the serum levels of IL-27 and IL-12, we could know whether the lower levels of IL-27 are related to clinical situations other than osteosarcoma. We found that, in line with the results of IL-27, serum IL-12 levels were lower in osteosarcoma patients compared with healthy controls, and these two cytokines were positively correlated, suggesting that low serum IL-27 levels may be a more general phenomenon in osteosarcoma patients. Next, we investigated the association of IL-27 with clinical features of osteosarcoma patients; the results showed that IL-27 was not related to the patients’ age, gender, tumor size, histological type, and location. Distinct low serum IL-27 levels were presented in osteosarcoma patients of clinical stages III-IV and with tumor metastasis, indicating that low serum IL-27 levels were related to the progression of osteosarcoma.

We noted that the data from previous epidemiological studies in diverse ethnic populations were inconsistent with our results. In the present study, the allele frequencies of the IL-27 -964 G, 2905 T, and 4730 C among the healthy controls were 0.352, 0.090, and 0.086, respectively, which were similar to the frequencies observed in other Chinese reports, but higher than the frequencies observed in healthy Koreans, suggesting that the distribution of IL-27 gene frequencies might vary among different ethnic groups. With respect to the IL-27 polymorphism, we found that serum IL-27p28 levels were lower in osteosarcoma than in controls, but we did not find any differences between serum IL-27p28 levels and IL-27 gene frequencies observed in 2 other Chinese reports.

We performed haplotype analysis of IL-27 gene in osteosarcoma patients and controls, respectively. However, none of the IL-27 haplotypes were not associated with osteosarcoma risk (P > 0.05).

|               | Osteosarcoma (2n = 320) (%) | Controls (2n = 500) (%) | OR (95% CI) | P   |
|---------------|-----------------------------|-------------------------|-------------|-----|
| A-964G-2905T-4730 | 203 (63.5)                  | 324 (64.8)              | 1.00        | —   |
| G-964T-2905T-4730 | 88 (27.4)                   | 147 (29.4)              | 0.77        | 0.217 |
| G-964G-2905T-4730 | 28 (8.7)                    | 44 (8.8)                | 1.01        | 0.982 |

CI = confidence interval, OR = odds ratio.

### DISCUSSION

IL-27 is produced by several antigen-presenting cells, such as lipopolysaccharide-stimulated monocytes and monocyte-derived dendritic cells. The biological functions of IL-27 are mediated by WSX-1 that is highly expressed on CD4+ T lymphocytes and natural killer cells. IL-27 is also known to play multiple roles in the upregulation of Th1 cytokines as in the downregulation of Th2 factor GATA binding protein. Increased expression of IL-27 is found to be associated with reduced Th1 cell cytokine responses. However, none of the IL-27 haplotypes were not associated with osteosarcoma risk (P > 0.05).
sample size of population-bases study with other ethnicities involved is mandatory.

In summary, the present study suggests that low serum IL-27p28 levels may be associated with development and progression of osteosarcoma; however, IL-27 gene polymorphism and their haplotypes may not contribute susceptibility to the osteosarcoma risk.

REFERENCES

1. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75 (1 suppl):203–210.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
3. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15–32.
4. Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol. 2013;2:33.
5. Ligers A, Teleshova N, Masterman T, et al. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2:145–152.
6. Lucas S, Ghilardi N, Li J, et al. IL-27 regulates IL-12 responsiveness of naïve CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A. 2003;100:15047–15052.
7. Jankowski M, Kopinski P, Goe A. Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz). 2010;58:417–425.
8. Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein–Barr virus infection in B lymphocytes. J Virol. 1996;70:1143–1153.
9. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naïve CD4+ T cells. Immunity. 2002;16:779–790.
10. Chae SC, Li CS, Kim KM, et al. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet. 2007;52:355–361.
11. Huang N, Liu L, Wang XZ, et al. Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA Cell Biol. 2008;27:527–531.
12. Li CS, Zhang Q, Lee KJ, et al. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J Gastroenterol Hepatol. 2009;24:1692–1696.
13. Tao YP, Wang WL, Li SY, et al. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol. 2012;138:1891–1900.